Immunity to infection in IL-17-deficient mice and humans

European Journal of Immunology

Volumn 42, Issue 9, 2012, Pages 2246-2254

  Cypowyj, Sophie ^a   Picard, Capucine ^b,c,d   Maródi, László ^e   Casanova, Jean Laurent ^a,b,c,d   Puel, Anne ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b IMAGINE INSTITUTE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cytokines; IL 17; Infectious diseases

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; STAT1 PROTEIN; STAT3 PROTEIN;

ACINETOBACTER BAUMANNII; BACILLUS ANTHRACIS; CANDIDA ALBICANS; CHLAMYDIA; COXSACKIE VIRUS B; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; ESCHERICHIA COLI; GAIN OF FUNCTION MUTATION; HELICOBACTER PYLORI; HUMAN; IMMUNITY; INFECTION; INFLUENZA VIRUS; KLEBSIELLA PNEUMONIAE; LEISHMANIA MAJOR; LISTERIA MONOCYTOGENES; MISSENSE MUTATION; MUCOCUTANEOUS CANDIDIASIS; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; NEISSERIA GONORRHOEAE; NONHUMAN; PHENOTYPE; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; SALMONELLA TYPHIMURIUM; SCHISTOSOMA MANSONI; SEVERE COMBINED IMMUNODEFICIENCY; SKIN ABSCESS; STAPHYLOCOCCUS AUREUS; TOXOPLASMA GONDII; YERSINIA PESTIS;

ANIMALS; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; HUMANS; IMMUNITY; INFECTION; INTERLEUKIN-17;

EID: 84865793094     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242605     Document Type: Review

References (123)

1. Gaffen, S. L., Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 2009. 9: 556-567.
2. Wright, J. F., Bennett, F., Li, B., Brooks, J., Luxenberg, D. P., Whitters, M. J., Tomkinson, K. N., et al., The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J. Immunol. 2008. 181: 2799-2805.
3. Onishi, R. M. and Gaffen, S. L., Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010. 129: 311-321.
4. Kolls, J. K. and Khader, S. A., The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev. 2010. 21: 443-448.
5. Khader, S. A., Gaffen, S. L. and Kolls, J. K., Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2009. 2: 403-411.
6. Ye, P., Rodriguez, F. H., Kanaly, S., Stocking, K. L., Schurr, J., Schwarzenberger, P., Oliver, P., et al., Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 2001. 194: 519-527.
7. Garraud, K., Cleret, A., Mathieu, J., Fiole, D., Gauthier, Y., Quesnel-Hellmann, A. and Tournier, J. N., Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax. Infect. Immun. 2012. 80: 131-142.
8. Gopal, R., Lin, Y., Obermajer, N., Slight, S., Nuthalapati, N., Ahmed, M., Kalinski, P. et al., IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur. J. Immunol. 2012. 42: 364-373.
9. Crowe, C. R., Chen, K., Pociask, D. A., Alcorn, J. F., Krivich, C., Enelow, R. I., Ross, T. M., et al., Critical role of IL-17RA in immunopathology of influenza infection. J. Immunol. 2009. 183: 5301-5310.
10. Yu, J. J., Ruddy, M. J., Conti, H. R., Boonanantanasarn, K. and Gaffen, S. L., The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. Infect. Immun. 2008. 76: 4206-4213.
11. Algood, H. M., Allen, S. S., Washington, M. K., Peek, R. M., Jr., Miller, G. G. and Cover, T. L., Regulation of gastric B cell recruitment is dependent on IL-17 receptor A signaling in a model of chronic bacterial infection. J. Immunol. 2009. 183: 5837-5846.
12. Feinen, B., Jerse, A. E., Gaffen, S. L. and Russell, M. W., Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal Immunol. 2010. 3: 312-321.
13. Freitas, A., Alves-Filho, J. C., Victoni, T., Secher, T., Lemos, H. P., Sonego, F., Cunha, F. Q. et al., IL-17 receptor signaling is required to control polymicrobial sepsis. J. Immunol. 2009. 182: 7846-7854.
14. Cho, J. S., Pietras, E. M., Garcia, N. C., Ramos, R. I., Farzam, D. M., Monroe, H. R., Magorien, J. E., et al., IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 2010. 120: 1762-1773.
15. Kelly, M. N., Kolls, J. K., Happel, K., Schwartzman, J. D., Schwarzenberger, P., Combe, C., Moretto, M. et al., Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against toxoplasma gondii infection. Infect. Immun. 2005. 73: 617-621.
16. Guiton, R., Vasseur, V., Charron, S., Arias, M. T., Van Langendonck, N., Buzoni-Gatel, D., Ryffel, B. et al., Interleukin 17 receptor signaling is deleterious during Toxoplasma gondii infection in susceptible BL6 mice. J. Infect. Dis. 2010. 202: 427-435.
17. Conti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., et al., Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 2009. 206: 299-311.
18. Huang, W., Na, L., Fidel, P. L. and Schwarzenberger, P., Requirement of interleukin-17A for systemic anti-candida albicans host defense in mice. J. Infect. Dis. 2004. 190: 624-631.
19. Meeks, K. D., Sieve, A. N., Kolls, J. K., Ghilardi, N. and Berg, R. E., IL-23 is required for protection against systemic infection with Listeria monocytogenes. J. Immunol. 2009. 183: 8026-8034.
20. Ishigame, H., Kakuta, S., Nagai, T., Kadoki, M., Nambu, A., Komiyama, Y., Fujikado, N., et al., Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009. 30: 108-119.
21. Sivick, K. E., Schaller, M. A., Smith, S. N. and Mobley, H. L., The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J. Immunol. 2010. 184: 2065-2075.
22. Lin, J. S., Kummer, L. W., Szaba, F. M. and Smiley, S. T., IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J. Immunol. 2011. 186: 1675-1684.
23. Okamoto Yoshida, Y., Umemura, M., Yahagi, A., O'Brien, R. L., Ikuta, K., Kishihara, K., Hara, H., et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J. Immunol. 2010. 184: 4414-4422.
24. Henningsson, L., Jirholt, P., Lindholm, C., Eneljung, T., Silverpil, E., Iwakura, Y., Linden, A. et al., Interleukin-17A during local and systemic Staphylococcus aureus-induced arthritis in mice. Infect Immun. 2010. 78: 3783-3790.
25. Shi, Y., Liu, X. F., Zhuang, Y., Zhang, J. Y., Liu, T., Yin, Z., Wu, C., et al., Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J. Immunol. 2010. 184: 5121-5129.
26. Lopez Kostka, S., Dinges, S., Griewank, K., Iwakura, Y., Udey, M. C. and von Stebut, E., IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J. Immunol. 2009. 182: 3039-3046.
27. Saijo, S., Ikeda, S., Yamabe, K., Kakuta, S., Ishigame, H., Akitsu, A., Fujikado, N., et al., Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 2010. 32: 681-691.
28. Kagami, S., Rizzo, H. L., Kurtz, S. E., Miller, L. S. and Blauvelt, A., IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J. Immunol. 2010. 185: 5453-5462.
29. Vinh, D. C., Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect. Dis. 2011. 11: 780-792.
30. Al-Herz, W., Bousfiha, A., Casanova, J. L., Chapel, H., Conley, M. E., Cunningham-Rundles, C., Etzioni, A., et al., Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Frontier in Immunol. 2011. 2: 1-26.
31. Ramos, E. S. M., Lima, C. M., Schechtman, R. C., Trope, B. M. and Carneiro, S., Superficial mycoses in immunodepressed patients (AIDS). Clin. Dermatol. 2010. 28: 217-225.
32. Virgili, A., Zampino, M. R. and Mantovani, L., Fungal skin infections in organ transplant recipients. Am. J. Clin. Dermatol. 2002. 3: 19-35.
33. Ochs, H. D., Smith, C. I., Puck, J. M., Primary immunodeficiency diseases: a molecular and genetic approach. Oxford Univ. Press 2012.
34. Morgan, N. V., Goddard, S., Cardno, T. S., McDonald, D., Rahman, F., Barge, D., Ciupek, A., et al., Mutation in the TCRalpha subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRalphabeta+ T cells. J. Clin. Invest. 2011. 121: 695-702.
35. Feske, S., Picard, C. and Fischer, A., Immunodeficiency due to mutations in ORAI1 and STIM1. Clin. Immunol. 2010. 135: 169-182.
36. Picard, C., Casanova, J. L. and Puel, A., Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clin. Microbiol. Rev. 2011. 24: 490-497.
37. Abdollahpour, H., Appaswamy, G., Kotlarz, D., Diestelhorst, J., Beier, R., Schaffer, A. A., Gertz, E. M., et al., The phenotype of human STK4 deficiency. Blood 2012. 119: 3450-3457.
38. Caudy, A. A., Reddy, S. T., Chatila, T., Atkinson, J. P. and Verbsky, J. W., CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 2007. 119: 482-487.
39. Sharfe, N., Dadi, H. K., Shahar, M. and Roifman, C. M., Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA 1997. 94: 3168-3171.
40. Hambleton, S., Salem, S., Bustamante, J., Bigley, V., Boisson-Dupuis, S., Azevedo, J., Fortin, A., et al., IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 2011. 365: 127-138.
41. Su, H. C., Jing, H. and Zhang, Q., DOCK8 deficiency. Ann. NY Acad. Sci. 2010. 1246: 26-33.
42. Ma, C. S., Chew, G. Y., Simpson, N., Priyadarshi, A., Wong, M., Grimbacher, B., Fulcher, D. A., et al., Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 2008. 205: 1551-1557.
43. Minegishi, Y., Saito, M., Nagasawa, M., Takada, H., Hara, T., Tsuchiya, S., Agematsu, K., et al., Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J. Exp. Med. 2009. 206: 1291-1301.
44. de Beaucoudrey, L., Puel, A., Filipe-Santos, O., Cobat, A., Ghandil, P., Chrabieh, M., Feinberg, J., et al., Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 2008. 205: 1543-1550.
45. Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., et al., Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008. 452: 773-776.
46. Renner, E. D., Rylaarsdam, S., Anover-Sombke, S., Rack, A. L., Reichenbach, J., Carey, J. C., Zhu, Q., et al., Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol. 2008. 122: 181-187.
47. Zhou, L., Ivanov, II, Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D. E., et al., IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007. 8: 967-974.
48. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L. et al., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006. 441: 235-238.
49. Filipe-Santos, O., Bustamante, J., Chapgier, A., Vogt, G., de Beaucoudrey, L., Feinberg, J., Jouanguy, E., et al., Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 2006. 18: 347-361.
50. de Beaucoudrey, L., Samarina, A., Bustamante, J., Cobat, A., Boisson-Dupuis, S., Feinberg, J., Al-Muhsen, S., et al., Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Med. (Baltimore). 2010. 89: 381-402.
51. Glocker, E. O., Hennigs, A., Nabavi, M., Schaffer, A. A., Woellner, C., Salzer, U., Pfeifer, D., et al., A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 2009. 361: 1727-1735.
52. Netea, M. G. and Marodi, L., Innate immune mechanisms for recognition and uptake of candida species. Trends Immunol. 2010. 31: 346-353.
53. Kisand, K., Boe Wolff, A. S., Podkrajsek, K. T., Tserel, L., Link, M., Kisand, K. V., Ersvaer, E., et al., Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 2010. 207: 299-308.
54. Puel, A., Doffinger, R., Natividad, A., Chrabieh, M., Barcenas-Morales, G., Picard, C., Cobat, A., et al., Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 2010. 207: 291-297.
55. Kisand, K., Lilic, D., Casanova, J. L., Peterson, P., Meager, A. and Willcox, N., Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur. J. Immunol. 2011. 41: 1517-1527.
56. Puel, A., Picard, C., Cypowyj, S., Lilic, D., Abel, L. and Casanova, J. L., Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr. Opin. Immunol. 2010. 22: 467-474.
57. Chilgren, R. A., Quie, P. G., Meuwissen, H. J. and Hong, R., Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet 1967. 2: 688-693.
58. Williamson, D. M., Chronic hyperplastic candidiasis and squamous carcinoma. Brit. J. Dermatol. 1969. 81: 125-127.
59. Wells, R. S., Higgs, J. M., Macdonald, A., Valdimarsson, H. and Holt, P. J., Familial chronic muco-cutaneous candidiasis. J. Med. Genet. 1972. 9: 302-310.
60. Blizzard, R. M. and Gibbs, J. H., Candidiasis: studies pertaining to its association with endocrinopathies and pernicious anemia. Pediatrics 1968. 42: 231-237.
61. Goldberg, L. S., Bluestone, R., Barnett, E. V. and Landau, J. W., Studies on lymphocyte and monocyte function in chronic mucocutaneous candidiasis. Clin. Exp. Immunol. 1971. 8: 37-43.
62. Levy, R. L., Bach, M. L., Huang, S., Bach, F. H., Hong, R., Ammann, A. J., Bortin, M. et al., Thymic transplantation in a case of chronic mucocutaneous candidiasis. Lancet 1971. 2: 898-900.
63. Lehner, T., Wilton, J. M. and Ivanyi, L., Immunodeficiencies in chronic muco-cutaneous candidosis. Immunology 1972. 22: 775-787.
64. Valdimarsson, H., Moss, P. D., Holt, P. J. and H., Obbs. Jr., Treatment of chronic mucocutaneous candidiasis with leucocytes from HL-A compatible sibling. Lancet 1972. 1: 469-472.
65. Higgs, J. M. and Wells, R. S., Chronic muco-cutaneous candidiasis: associated abnormalities of iron metabolism. Brit. J. Derm. 1972. 86: 88-102.
66. Kirkpatrick, C. H., Rich, R. R., Graw, R. G., Jr., Smith, T. K., Mickenberg, I. and Rogentine, G. N., Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. Clin. Exp. Immunol. 1971. 9: 733-748.
67. Canales, L., Middlemas, R. O., 3rd, Louro, J. M. and South, M. A., Immunological observations in chronic mucocutaneous candidiasis. Lancet 1969. 2: 567-571.
68. Wells, R. S., Chronic oral candidiasis (autosomal recessive inheritance) (three cases). Proc. R. Soc. Med. 1970. 63: 890-891.
69. Eyerich, K., Foerster, S., Rombold, S., Seidl, H. P., Behrendt, H., Hofmann, H., Ring, J. et al., Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J. Invest. Dermatol. 2008. 128: 2640-2645.
70. Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., et al., Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011. 332: 65-68.
71. Buckley, R. H., Lucas, Z. J., Hattler, B. G., Jr., Zmijewski, C. M. and Amos, D. B., Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin. Exp. Immunol. 1968. 3: 153-169.
72. Bader, O., Weig, M. S., Gross, U., Schon, M. P., Mempel, M. and Buhl, T., Photo quiz. A 32-year-old man with ulcerative mucositis, skin lesions, and nail dystrophy. Chronic mucocutaneous candidiasis by multidrug-resistant Candida albicans. Clin. Infect. Dis. 2012. 54: 972, 1035-1036.
73. Smeekens, S. P., Plantinga, T. S., van de Veerdonk, F. L., Heinhuis, B., Hoischen, A., Joosten, L. A., Arkwright, P. D., et al., STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One 2011. 6: e29248, 1-7.
74. van de Veerdonk, F. L., Plantinga, T. S., Hoischen, A., Smeekens, S. P., Joosten, L. A., Gilissen, C., Arts, P., et al., STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 2011. 365: 54-61.
75. Liu, L., Okada, S., Kong, X. F., Kreins, A. Y., Cypowyj, S., Abhyankar, A., Toubiana, J., et al., Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 2011. 208: 1635-1648.
76. Toth, B., Mehes, L., Tasko, S., Szalai, Z., Tulassay, Z., Cypowyj, S., Casanova, J. L., et al., Herpes in STAT1 mutation. Lancet 2012. 379: 2500.
77. Takezaki, S., Yamada, M., Kato, M., Park, M. J., Maruyama, K., Yamazaki, Y., Chida, N., et al., Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J. Immunol. 2012. 189: 1521-1526.
78. Averbuch, D., Chapgier, A., Boisson-Dupuis, S., Casanova, J. L. and Engelhard, D., The clinical spectrum of patients with deficiency of signal transducer and activator of transcription-1. Pediatr. Infect. Dis. J. 2011. 30: 352-355.
79. Chapgier, A., Boisson-Dupuis, S., Jouanguy, E., Vogt, G., Feinberg, J., Prochnicka-Chalufour, A., Casrouge, A., et al., Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet. 2006. 2: 1193-1206.
80. Chapgier, A., Kong, X. F., Boisson-Dupuis, S., Jouanguy, E., Averbuch, D., Feinberg, J., Zhang, S. Y., et al., A partial form of recessive STAT1 deficiency in humans. J. Clin. Invest. 2009. 119: 1502-1514.
81. Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S., Harris, J., Holland, S. M., et al., Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001. 293: 300-303.
82. Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I. Z., Al-Jumaah, S., Yang, K., et al., Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 2003. 33: 388-391.
83. Kong, X. F., Ciancanelli, M., Al-Hajjar, S., Alsina, L., Zumwalt, T., Bustamante, J., Feinberg, J., et al., A novel form of human STAT1 deficiency impairing early but not late responses to interferons. Blood. 2010. 116: 5895-5906.
84. Kristensen, I. A., Veirum, J. E., Moller, B. K. and Christiansen, M., Novel STAT1 alleles in a patient with impaired resistance to mycobacteria. J. Clin. Immunol. 2011. 31: 265-271.
85. Boisson-Dupuis, S., Kong, X. F., Okada, S., Cypowyj, S., Puel, A., Abel, L. and Casanova, J. L., Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr. Opin. Immunol. 2012. 24: 364-378.
86. Yoshimura, T., Takeda, A., Hamano, S., Miyazaki, Y., Kinjyo, I., Ishibashi, T., Yoshimura, A. et al., Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J. Immunol. 2006. 177: 5377-5385.
87. Villarino, A. V., Gallo, E. and Abbas, A. K., STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J. Immunol. 2010. 185: 6461-6471.
88. Tanaka, K., Ichiyama, K., Hashimoto, M., Yoshida, H., Takimoto, T., Takaesu, G., Torisu, T., et al., Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J. Immunol. 2008. 180: 3746-3756.
89. Stumhofer, J. S., Laurence, A., Wilson, E. H., Huang, E., Tato, C. M., Johnson, L. M., Villarino, A. V., et al., Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 2006. 7: 937-945.
90. Ramgolam, V. S., Sha, Y., Jin, J., Zhang, X. and Markovic-Plese, S., IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 2009. 183: 5418-5427.
91. Liu, H. and Rohowsky-Kochan, C., Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein 1. J. Interferon Cytokine Res. 2011. 31: 459-469.
92. Guzzo, C., Che Mat, N. F. and Gee, K., Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J. Biol. Chem. 2010. 285: 24404-24411.
93. Feng, G., Gao, W., Strom, T. B., Oukka, M., Francis, R. S., Wood, K. J. and Bushell, A., Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3 +regulatory T cells. Eur. J. Immunol. 2008. 38: 2512-2527.
94. El-behi, M., Ciric, B., Yu, S., Zhang, G. X., Fitzgerald, D. C. and Rostami, A., Differential effect of IL-27 on developing versus committed Th17 cells. J. Immunol. 2009. 183: 4957-4967.
95. Diveu, C., McGeachy, M. J., Boniface, K., Stumhofer, J. S., Sathe, M., Joyce-Shaikh, B., Chen, Y., et al., IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 2009. 182: 5748-5756.
96. Crabe, S., Guay-Giroux, A., Tormo, A. J., Duluc, D., Lissilaa, R., Guilhot, F., Mavoungou-Bigouagou, U., et al., The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J. Immunol. 2009. 183: 7692-7702.
97. Chen, M., Chen, G., Nie, H., Zhang, X., Niu, X., Zang, Y. C., Skinner, S. M., et al., Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T cells in MS. Eur. J. Immunol. 2009. 39: 2525-2536.
98. Batten, M., Li, J., Yi, S., Kljavin, N. M., Danilenko, D. M., Lucas, S., Lee, J., et al., Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 2006. 7: 929-936.
99. Amadi-Obi, A., Yu, C. R., Liu, X., Mahdi, R. M., Clarke, G. L., Nussenblatt, R. B., Gery, I., et al., TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 2007. 13: 711-718.
100. Spolski, R. and Leonard, W. J., Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 2008. 26: 57-79.
101. Kishimoto, T., Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 2005. 23: 1-21.
102. Quintana-Murci, L., Alcais, A., Abel, L. and Casanova, J. L., Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat. Immunol. 2007. 8: 1165-1171.
103. Casanova, J. L. and Abel, L., The human model: a genetic dissection of immunity to infection in natural conditions. Nat. Rev. Immunol. 2004. 4: 55-66.
104. Alcais, A., Quintana-Murci, L., Thaler, D. S., Schurr, E., Abel, L. and Casanova, J. L., Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann. NY Acad. Sci. 2010. 1214: 18-33.
105. Alcais, A., Abel, L. and Casanova, J. L., Human genetics of infectious diseases: between proof of principle and paradigm. J. Clin. Invest. 2009. 119: 2506-2514.
106. Casanova, J. L. and Abel, L., Primary immunodeficiencies: a field in its infancy. Science 2007. 317: 617-619.
107. Casanova, J. L. and Abel, L., Inborn errors of immunity to infection: the rule rather than the exception. J. Exp. Med. 2005. 202: 197-201.
108. Casanova, J. L. and Abel, L., Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 2002. 20: 581-620.
109. Fieschi, C. and Casanova, J. L., The role of interleukin-12 in human infectious diseases: only a faint signature. Eur. J. Immunol. 2003. 33: 1461-1464.
110. Dorman, S. E., Picard, C., Lammas, D., Heyne, K., van Dissel, J. T., Baretto, R., Rosenzweig, S. D., et al., Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004. 364: 2113-2121.
111. Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G. and Russell, C. B., The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J. Invest. Dermatol. 2012. 194: 1-10.
112. Maddur, M. S., Miossec, P., Kaveri, S. V. and Bayry, J., Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am. J. Pathol. 2012. 181: 8-18.
113. Shahar, E., Kriboy, N. and Pollack, S., White cell enhancement in the treatment of severe candidosis. Lancet 1995. 346: 974-975.
114. Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D. et al., Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012. 366: 1190-1199.
115. Garber, K., Anti-IL-17 mAbs herald new options in psoriasis. Nat. Biotechnol. 2012. 30: 475-477.
116. Xu, S., Han, Y., Xu, X., Bao, Y., Zhang, M. and Cao, X., IL-17A-producing gammadeltaT cells promote CTL responses against Listeria monocytogenes infection by enhancing dendritic cell cross-presentation. J. Immunol. 2010. 185: 5879-5887.
117. Songhet, P., Barthel, M., Rohn, T. A., Van Maele, L., Cayet, D., Sirard, J. C., Bachmann, M., et al., IL-17A/F-signaling does not contribute to the initial phase of mucosal inflammation triggered by S. Typhimurium. PLoS One 2010. 5: e13804, 1-10.
118. Mayuzumi, H., Inagaki-Ohara, K., Uyttenhove, C., Okamoto, Y. and Matsuzaki, G., Interleukin-17A is required to suppress invasion of Salmonella enterica serovar typhimurium to enteric mucosa. Immunology 2010. 131: 377-385.
119. Scurlock, A. M., Frazer, L. C., Andrews, C. W., Jr., O'Connell, C. M., Foote, I. P., Bailey, S. L., Chandra-Kuntal, K., et al., Interleukin-17 contributes to generation of Th1 immunity and neutrophil recruitment during Chlamydia muridarum genital tract infection but is not required for macrophage influx or normal resolution of infection. Infect. Immun. 2011. 79: 1349-1362.
120. Breslow, J. M., Meissler, J. J., Jr., Hartzell, R. R., Spence, P. B., Truant, A., Gaughan, J. and Eisenstein, T. K., Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect. Immun. 2011. 79: 3317-3327.
121. Wozniak, K. L., Hardison, S. E., Kolls, J. K. and Wormley, F. L., Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One 2011. 6: e17204, 1-10.
122. Rutitzky, L. I. and Stadecker, M. J., Exacerbated egg-induced immunopathology in murine Schistosoma mansoni infection is primarily mediated by IL-17 and restrained by IFN-gamma. Eur. J. Immunol. 2011. 41: 2677-2687.
123. Fan, Y., Weifeng, W., Yuluan, Y., Qing, K., Yu, P. and Yanlan, H., Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation. Virol. J. 2011. 8: 17, 1-7.